Zai Lab (NASDAQ:ZLAB) Sets New 1-Year Low at $14.01

Shares of Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as $14.01 and last traded at $14.23, with a volume of 72641 shares. The stock had previously closed at $14.20.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ZLAB shares. Citigroup dropped their price target on shares of Zai Lab from $123.00 to $66.00 and set a "buy" rating for the company in a research note on Thursday, February 29th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a research note on Friday, January 12th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $64.22.

Zai Lab Stock Performance

The business's fifty day moving average is $18.28 and its two-hundred day moving average is $23.12. The company has a market cap of $1.43 billion, a P/E ratio of -4.18 and a beta of 1.10.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.11). Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. The company had revenue of $65.83 million for the quarter, compared to the consensus estimate of $70.41 million. Analysts expect that Zai Lab Limited will post -3.1 EPS for the current fiscal year.

Insider Activity at Zai Lab

In other Zai Lab news, insider Joshua L. Smiley sold 1,988 shares of the firm's stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $15.67, for a total transaction of $31,151.96. Following the transaction, the insider now owns 28,684 shares of the company's stock, valued at approximately $449,478.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Zai Lab news, insider Rafael Amado sold 2,544 shares of the firm's stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $18.86, for a total transaction of $47,979.84. Following the transaction, the insider now owns 20,093 shares of the company's stock, valued at approximately $378,953.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joshua L. Smiley sold 1,988 shares of Zai Lab stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $31,151.96. Following the completion of the transaction, the insider now directly owns 28,684 shares in the company, valued at approximately $449,478.28. The disclosure for this sale can be found here. Insiders sold 12,568 shares of company stock worth $208,508 in the last 90 days. 5.23% of the stock is owned by corporate insiders.

Institutional Trading of Zai Lab

Several large investors have recently bought and sold shares of ZLAB. Aviva PLC boosted its position in Zai Lab by 1.1% in the 1st quarter. Aviva PLC now owns 35,870 shares of the company's stock worth $1,578,000 after purchasing an additional 400 shares in the last quarter. Ensign Peak Advisors Inc grew its holdings in Zai Lab by 7.3% in the third quarter. Ensign Peak Advisors Inc now owns 5,850 shares of the company's stock valued at $200,000 after purchasing an additional 400 shares during the period. National Pension Service grew its stake in Zai Lab by 2.4% in the 3rd quarter. National Pension Service now owns 18,356 shares of the company's stock valued at $644,000 after acquiring an additional 423 shares during the period. Voya Investment Management LLC raised its position in Zai Lab by 5.2% during the fourth quarter. Voya Investment Management LLC now owns 9,013 shares of the company's stock worth $277,000 after acquiring an additional 443 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in Zai Lab by 45.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,767 shares of the company's stock valued at $48,000 after purchasing an additional 548 shares in the last quarter. Hedge funds and other institutional investors own 41.65% of the company's stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.